首頁 »
October 28, 2016

競爭企業分析:Avastin、Cyramza、Eylea、Lucentis的抗VEGF/R生技仿製藥及 Bio-Supe


競爭企業分析:Avastin、Cyramza、Eylea、Lucentis的抗VEGF/R生技仿製藥及 Bio-Superior
Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - 2016 Update
出版商 La Merie Publishing 商品編碼 358307 出版日期 2016年02月29日 內容資訊 英文 46 Pages 價格
USD 440 PDF by E-mail (Single User License)
USD 880 PDF by E-mail (Site License)
USD 1,320 PDF by E-mail (Global License)
競爭企業分析:Avastin、Cyramza、Eylea、Lucentis的抗VEGF/R生技仿製藥及 Bio-Superior Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - 2016 Update
出版日期: 2016年02月29日 內容資訊: 英文 46 Pages
以血管內皮層生長因子 (VEGF) 或VEGF受體 (VEGF-R) 為標的治療抗體,2015年整體銷售額為150億美元,是極為成功的產品類別。Avastin是多年的生技藥品暢銷者,不過,視網膜疾病治療用的抗VEGF產品,Lucentis、Eylea,2015年第一次記錄了比癌症治療用的抗VEGF/R產品高的銷售額。
本報告提供各種癌症的症狀、視網膜疾病的治療所採用的血管內皮層生長因子 (VEGF) 此外關於以其受體 (VEGF-R) 為標的之重組抗體領域中的競爭產品評價,在各產品的銷售額、症狀的組合、開發平台,標的抗體、蛋白質的開發中現在進行中的計劃相關資訊等。
第1章 癌症中抗VEGF/R上市藥
 Avastin、Zaltrap、Cyramza的銷售額
 Avastin的銷售額及症狀的組合
 Zaltrap的銷售額及症狀的組合
 Cyramza的銷售額及症狀的組合
第2章 Avastin、Zaltrap的抗VEGF Bio-Superior
 癌症中抗VEGF Bio-Superior的開發平台
 癌症的雙特異性抗VEGF的開發平台
第3章 Cyramza的抗VEGF-R Bio-Superior
 癌症中抗VEGF-R Bio-Superior的開發平台
 癌症的雙特異性抗VEGF-R的開發平台
第4章 癌症的Avastin生技仿製藥的開發平台
第5章 眼科中抗VEGF上市藥
 Lucentis、Eylea的銷售額
 Lucentis的銷售額及症狀的組合
 Eylea的銷售額及症狀的組合
第6章 Lucentis、Eylea的抗VEGF Bio-Superior
 眼科中抗VEGF Bio-Superior
 眼科的 Bio-Superior雙特異性抗VEGF、抗VEGF並用藥
第7章 眼科其他的抗VEGF分子
第8章 眼科的Lucentis的生技仿製藥
第9章 眼科的Eylea的生技仿製藥
第10章 眼科中抗VEGF的非標籤藥物使用 (非適應症使用)
Product Code: LMCA0124
The Competitive Intelligence Report "Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - a 2016 Update " provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) for treatment of a variety of cancer indications and retinal diseases as of February 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) are a highly successful class of products as evidenced by total sales of US$ 15 bln in 2015. While Avastin has been known for years as a blockbuster biologic, anti-VEGF products Lucentis and Eylea for treatment of retinal diseases posted for the first time in 2015 higher sales than the anti-VEGF/R products for cancer treatment. The commercial success of Avastin as a single product approved for many cancer indications and the forthcoming patent expiries in the major markets have attracted a number of biosimilar developments in advanced clinical stages.
Until now, less attention has been paid to anti-VEGF antibodies used for treatment of ophthalmic diseases although the approved antibody products are attractive targets for the second wave of biosimilar antibodies because of the impressive market growth fueled by the clinical success and patent expiries in the mid-term.
The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies or proteins for treatment of cancer and neo-angiogenic eye diseases. Competitor projects are listed in a tabular format providing information on:
 Drug Codes,
 Target / Mechanism of Action,
 Class of Compound,
 Company,
 Product Category,
 Indication,
 R&D Stage and
 additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Table of Contents
1) Marketed Anti-VEGF/R Products in Oncology
 Avastin, Zaltrap & Cyramza Sales 2008 - 2015
 Avastin Sales and Indication Portfolio
 Zaltrap Sales and Indication Portfolio
 Cyramza Sales and Indication Portfolio
2) Anti-VEGF Biosuperiors of Avastin and Zaltrap
 Anti-VEGF Biosuperior Pipeline in Oncology
 Bispecific Anti-VEGF Pipeline in Oncology
3) Anti-VEGF-R Biosuperiors of Cyramza
 Anti-VEGF-R Biosuperior Pipeline in Oncology
 Bispecific Anti-VEGF-R Pipeline in Oncology
4) Avastin Biosimilar Pipeline in Oncology
5) Marketed Anti-VEGF Products in Ophthalmology
 Lucentis & Eylea Sales 2008 - 2015
 Lucentis Sales & Indication Portfolio
 Eylea Sales & Indication Portfolio
6) Anti-VEGF Biosuperiors of Lucentis and Eylea
 Biosuperior Anti-VEGF in Ophthalmology
 Biosuperior Bispecific Anti-VEGF and Anti-VEGF Combinations in Ophthalmology
7) Other Anti-VEGF Molecules in Ophthalmology
8) Lucentis Biosimilars in Ophthalmology
9) Eylea Biosimilars in Ophthalmology
10) Off-Label Use of Anti-VEGF in Ophthalmology

http://www.giichinese.com.tw/report/lmer358307-competitor-analysis-anti-vegf-r-biosimilars.html


藥名(學名)DAPSONE←上一篇 │首頁│ 下一篇→眼鏡補助6千、輪椅補助1萬2...長輩用的政府都有補貼